Rodyklė 
 Ankstesnis 
 Kitas 
 Visas tekstas 
Procedūra : 2018/2775(RSP)
Procedūros eiga plenarinėje sesijoje
Dokumento priėmimo eiga : B8-0071/2019

Pateikti tekstai :

B8-0071/2019

Debatai :

PV 12/02/2019 - 24
CRE 12/02/2019 - 24

Balsavimas :

PV 13/02/2019 - 16.11
CRE 13/02/2019 - 16.11
Balsavimo rezultatų paaiškinimas

Priimti tekstai :

P8_TA(2019)0113

Diskusijos
Trečiadienis, 2019 m. vasario 13 d. - Strasbūras Atnaujinta informacija

16.11. Kanapių naudojimas gydymo tikslais (B8-0071/2019) (balsavimas)
Kalbų vaizdo įrašas
PV
 

- Prima della votazione sull'emendamento 11:

 
  
MPphoto
 

  Luke Ming Flanagan (GUE/NGL). – Mr President, the reason for the oral amendment is we have left two members of the cannabis family out of what should have been there. It should also include cannabis indica and cannabis ruderalis. Cannabis ruderalis has very low amounts of tetrahydrocannabinol (THC) in comparison to cannabidiol, which is what some people want here and cannabis indica has a better balance of cannabidiol with THC, so if you want to do it right, include this.

 
  
MPphoto
 

  Dubravka Šuica, on behalf of the PPE Group. – Mr President, on behalf of the PPE Group, I object to this oral amendment.

 
  
 

(L'emendamento orale non è accolto vista l'opposizione di oltre 40 deputati presenti in aula)

 
Atnaujinta: 2019 m. gegužės 24 d.Teisinis pranešimas - Privatumo politika